RxDoctor Payments Data

Rachel Klepps, APRN

Family · Appleton, WINPI 1811564073

Payments from drug & device makers

$2,197in general payments, 2019–2025

Across 27 payments — averaging $81.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Edwards Lifesciences$296
  • AstraZeneca$228
  • Actelion Pharmaceuticals US, Inc.$113
  • Abbott$109
  • Heartflow, Inc.$67
  • plus $135 from 4 others

What the payments were for

  • Travel & lodging$53024%
  • Food & beverage$1,57872%
  • Education$894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,197 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,889
Medicare patients
110
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol108$89,358
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$81,120
Spiriva RespimatTiotropium Bromide52$35,517
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$22,461
EliquisApixaban22$21,151
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$19,992
JardianceEmpagliflozin21$19,033
Spiriva HandihalerTiotropium Bromide19$18,641
Incruse ElliptaUmeclidinium Bromide34$15,452
Arnuity ElliptaFluticasone Furoate40$13,219
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$10,611
Combivent RespimatIpratropium/Albuterol Sulfate14$9,373
Advair HfaFluticasone Propion/Salmeterol23$9,020
EntrestoSacubitril/Valsartan11$7,005
Wixela InhubFluticasone Propion/Salmeterol52$6,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$228$89,358108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →